Thursday, January 19, 2023, San Francisco, California, 6:15 PM – 7:45 PM Pacific Time (9:15 PM – 10:45 PM Eastern Time)

Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Gastroesophageal Cancers

Part 2 of a 3-Part CME Symposium Series Held in Conjunction with the 2023 ASCO Gastrointestinal Cancers Symposium

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Program Schedule — Pacific Time
5:45 PM – 6:15 PM — Registration and Dinner
6:15 PM – 7:45 PM — Educational Meeting

Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)

This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.  
Yelena Y Janjigian, MD
Associate Professor
Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Florian Lordick, MD, PhD
Full Professor of Medicine at the University
of Leipzig
Director of the University Cancer Center
Head of Department of Oncology
Leipzig University
Leipzig, Germany

Zev Wainberg, MD, MSc
Co-Director, GI Oncology Program
Director of Early Phase Clinical Research
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Samuel J Klempner, MD
Associate Professor
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, and Lilly.
Program Schedule — Pacific Time
5:45 PM – 6:15 PM — Registration and Dinner Buffet
6:15 PM – 7:45 PM — Educational Meeting

MODULE 1: Optimizing the Selection of Therapy for Newly Diagnosed Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer

  • Design, eligibility criteria and key efficacy and safety endpoints evaluated in the Phase III CheckMate 649 study comparing first-line nivolumab/chemotherapy or nivolumab/ipilimumab to chemotherapy alone for advanced gastroesophageal adenocarcinoma
  • Major efficacy and safety findings reported from the CheckMate 649 trial; impact of PD-L1 expression on outcomes
  • FDA-approved indication for nivolumab in combination with chemotherapy as first-line treatment and optimal incorporation into current management algorithms
  • Outcomes observed with first-line pembrolizumab with or without chemotherapy in the Phase III KEYNOTE-062 trial; implications, if any, for clinical care
  • Frequency of microsatellite instability-high (MSI-H) status in patients with gastroesophageal adenocarcinoma; implications for current clinical care
  • Published findings from the Phase II NEONIPIGA trial evaluating nivolumab/ipilimumab as neoadjuvant therapy for locally advanced, resectable MSI-H gastric adenocarcinoma

MODULE 2: Current Considerations in the Treatment of HER2-Positive Advanced Gastric/GEJ Adenocarcinoma

  • Frequency of HER2 amplification in advanced gastric/GEJ cancer; current management approaches for HER2-positive disease in the newly diagnosed and relapsed/refractory (R/R) settings
  • Principal outcomes from the Phase III KEYNOTE-811 trial supporting the use of first-line pembrolizumab/trastuzumab/chemotherapy for metastatic HER2-positive gastric/GEJ adenocarcinoma
  • Historical experience with HER2-targeting agents (eg, lapatinib, pertuzumab, trastuzumab emtansine) for patients who experience disease progression on trastuzumab-based therapy
  • Published efficacy and safety data with T-DXd for Asian (DESTINY-Gastric01) and Western (DESTINY-Gastric02) patients with progressive HER2-positive gastric/GEJ cancer
  • Spectrum, incidence and severity of toxicities, including interstitial lung disease, with T-DXd for gastric cancer
  • FDA approval for T-DXd; optimal sequencing for patients with progressive HER2-positive disease
  • Ongoing clinical trials (eg, DESTINY-Gastric03, DESTINY-Gastric04) attempting to further define the role of T-DXd in gastric/GEJ cancer
  • Other promising agents/strategies (eg, tucatinib, zanidatamab) in clinical development for gastroesophageal cancers

MODULE 3: Selection and Sequencing of Therapy for R/R Gastric/GEJ Cancer; Novel Investigational Approaches

  • Published findings with and optimal integration of ramucirumab into current clinical algorithms for metastatic gastric/GEJ cancer; role of this agent for patients experiencing disease progression on an immune checkpoint inhibitor
  • Available clinical research supporting the FDA approval of TAS-102 for heavily pretreated metastatic gastric/GEJ cancer; patient selection for TAS-102 in routine practice
  • Rationale for, available data with and ongoing investigation of novel combination approaches (eg, ramucirumab with TAS-102 or anti-PD-1 antibodies)
  • Biologic rationale for targeting claudin 18.2 in gastric/GEJ cancer
  • Mechanism of action of and available efficacy and safety findings with zolbetuximab for advanced gastric/GEJ adenocarcinoma with claudin 18.2 expression
  • Frequency of FGFR2b overexpression in gastroesophageal cancers; mechanism of action of bemarituzumab
  • Major efficacy and safety data from the Phase II FIGHT trial evaluating bemarituzumab/chemotherapy versus chemotherapy alone as first-line therapy for FGFR2b-positive metastatic gastric/GEJ cancer
  • Ongoing Phase III evaluations of zolbetuximab and bemarituzumab in combination with chemotherapy and/or immunotherapy; anticipated completion dates and potential clinical roles for each
  • Other promising novel agents and strategies under investigation for gastroesophageal cancers

MODULE 4: Current Approaches to the Management of Esophageal Cancer

  • Clinical and biologic factors affecting choice of therapy for patients with esophageal cancer
  • Design, eligibility criteria and primary and secondary endpoints of the Phase III CheckMate 577 study evaluating nivolumab as adjuvant therapy for patients with resected esophageal or GEJ cancer
  • Available efficacy and safety outcomes from CheckMate 577; recent FDA approval and optimal patient selection for use
  • Published data from the Phase III CheckMate 648 study of nivolumab/chemotherapy and nivolumab/ipilimumab versus chemotherapy alone for advanced squamous cell carcinoma of the esophagus; recent FDA approval of these regimens
  • Design, eligibility criteria and major findings from the Phase III KEYNOTE-590 study evaluating first-line pembrolizumab combined with chemotherapy versus chemotherapy alone for advanced esophageal cancer; current role in clinical practice
  • Other promising immune checkpoint inhibitor-based strategies for advanced esophageal and GEJ cancer

Target Audience
This activity is intended for medical and radiation oncologists, nurses, hematology-oncology fellows, surgeons and other healthcare professionals involved in the treatment of gastrointestinal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Use HER2 status, PD-L1 combined positive score, microsatellite instability status, clinical factors and patient preferences to personalize the selection of first-line therapy for patients with locally advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancer.
  • Describe the published research data with the use of anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies for the management of gastric, GEJ and esophageal cancer, and strategically integrate these agents into nonprotocol treatment algorithms.
  • Optimally incorporate available therapeutic agents and regimens into the management of HER2-negative metastatic gastric, GEJ and esophageal cancer that has progressed on front-line therapy.
  • Appraise clinical trial findings with and discern the clinical applicability of adjuvant anti-PD-1 antibody therapy for patients with resected esophageal/GEJ cancer who have received neoadjuvant chemoradiation therapy and have residual pathologic disease.
  • Recall available data with novel HER2-targeted agents and strategies for newly diagnosed and previously treated HER2-overexpressing gastric/GEJ cancer, and identify candidates who may be appropriate for these approaches.
  • Recognize common and rare side effects associated with approved and investigational agents for gastroesophageal cancer, and apply this information to develop appropriate and effective supportive management plans.
  • Review the rationale for, available data with and ongoing studies evaluating novel agents and strategies for gastroesophageal cancers, and effectively prioritize clinical trial opportunities for eligible patients.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, and Lilly.

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)

The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Convention Center, where the 2023 ASCO Gastrointestinal Cancers Symposium is taking place.

This activity is intended for medical and radiation oncologists, nurses, hematology-oncology fellows, surgeons and other healthcare professionals involved in the treatment of gastrointestinal cancers.

There is no fee to participate in this hybrid event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.

​ ​
IN-PERSON registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

In-Person Registration for clinicians in practice »
IN-PERSON registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

In-Person Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.


Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.


Not an official event of the 2023 ASCO Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.